Percheron Updates Timetable for $2.2m Entitlement Offer Ahead of 2026 Trials

An announcement from Percheron Therapeutics ( (AU:PER) ) is now available.

Percheron Therapeutics has updated the timetable for its previously announced non-renounceable entitlement offer, which aims to raise up to approximately $2.2 million. The revised schedule adjusts the ex date and record date, and sets out key milestones including dispatch of offer documents on 24 March 2026, a closing date of 8 April 2026, and anticipated quotation of new shares on 16 April 2026, with all dates remaining indicative and subject to change under ASX rules.

The entitlement offer’s proceeds are expected to support Percheron’s ongoing operations and its pipeline of oncology and rare disease therapies, including further clinical development of its lead antibody program HMBD-002. The capital raise and updated timetable underscore the company’s efforts to secure funding ahead of planned 2026 clinical trials, which may influence its competitive position in the immuno-oncology sector and be relevant for existing shareholders assessing participation in the offer.

The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.

More about Percheron Therapeutics

Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercialising novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator VISTA, which has completed a phase I trial in advanced cancer patients showing it to be generally safe and well tolerated, with further clinical trials planned in 2026.

Technical Sentiment Signal: Sell

Current Market Cap: A$6.52M

For detailed information about PER stock, go to TipRanks’ Stock Analysis page.